High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths,
and overall survival has not changed significantly for several decades. In this Opinion article …

Aggressive and recurrent gynecological cancers are associated with worse prognosis and a
lack of effective therapeutic response. Ovarian cancer (OC) patients are often diagnosed in …

Paclitaxel is recommended as a first-line chemotherapeutic agent against ovarian cancer,
but drug resistance becomes a major limitation of its success clinically. The key molecule or …

Angiogenesis is a process of neovascular formation from pre-existing blood vessels, which
consists of sequential steps for vascular destabilization, angiogenic sprouting, lumen …

Clear cell carcinoma (CCC) of the ovary is known to show poorer sensitivity to
chemotherapeutic agents and to be associated with a worse prognosis than the more …

There is an urgent need for improved therapy for advanced ovarian carcinoma, which may
be met by administering immune-modulatory monoclonal antibodies (mAbs) to generate a …

Epithelial ovarian cancer remains the most lethal gynecologic malignancy. During the last
15 years, there has been only marginal improvement in 5 year overall survival. These …

The secretome of cancer and stromal cells generates a microenvironment that contributes to
tumour cell invasion and angiogenesis. Here we compare the secretome of human …

Fc-fusion proteins are composed of Fc region of IgG antibody (Hinge-CH2-CH3) and a
desired linked protein. Fc region of Fc-fusion proteins can bind to neonatal Fc receptor …

Ovarian cancer remains the most lethal gynecologic cancer and new targeted molecular
therapies against this miserable disease continue to be challenging. In this study, we …